7	25	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 8), 'text':'Deregulated protein kinases have been linked to numerous diseases'}, {'start':(0, 9), 'end':(0, 17), 'text':'including cancer and diabetes as well as inflammation .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 19), 'text':'The targeted inhibition of protein tyrosine kinases is now well established as an effective therapeutic regimen for chronic myeloid leukemia'}, {'start':(1, 20), 'end':(1, 28), 'text':'( CML ) and several solid tumors - .'}]}, {'start':(2, 0), 'end':(2, 18), 'text':'Many small-molecule kinase inhibitors have exploited a conserved threonine residue within the ATP binding site for binding specificity .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 15), 'text':'This threonine controls access of the inhibitors to a hydrophobic pocket deep in the active site'}, {'start':(3, 16), 'end':(3, 34), 'text':'that is not contacted by ATP , hence leading to its designation as a \' gatekeeper \' residue .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 22), 'text':'Substitution of the gatekeeper threonine residue with bulky side chains is a common mechanism of resistance to pharmacological ATP-competitive kinase inhibitors , .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 15), 'text':'Imatinib has been used successfully to inhibit BCR-ABL in CML , c-KIT in gastrointestinal stromal tumor'}, {'start':(5, 16), 'end':(5, 30), 'text':'( GIST ) and platelet derived growth factor receptor-alpha ( PDGFRA ) in hypereosinophilic syndrome'}]}, {'start':(5, 31), 'end':(5, 35), 'text':'( HES ) , .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 4), 'text':'The first imatinib resistant mutation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 5), 'end':(6, 17), 'text':'described in CML patients was an isoleucine substitution at the gatekeeper residue Thr315'}, {'start':(6, 18), 'end':(6, 32), 'text':'( numbered according to the sequence for the type Ia isoform of c-ABL ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 23), 'text':'The T315I mutation has been detected in imatinib-naive CML patients and accounts for ~ 20 % of the total burden of clinical resistance .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 13), 'text':'Mutation at the analogous position to Thr315 in other imatinib targets such as c-KIT'}, {'start':(8, 14), 'end':(8, 37), 'text':'( Thr670 ) and PDGFRA ( Thr674 ) have been linked to imatinib resistance in patients with GIST and HES , respectively , .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(9, 0), 'end':(9, 14), 'text':'Similarly , the gatekeeper mutation T790M in EGFR causes resistance to gefitinib and erlotinib ,'}, {'start':(9, 15), 'end':(9, 42), 'text':'and has been detected in lung cancer patients before drug treatment and in the germ line of a family pedigree with several cases of lung cancer , .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(10, 0), 'end':(10, 31), 'text':'The association of gatekeeper residue mutations with malignancy even in the absence of treatment with kinase inhibitors implies a role in activation of the transforming function of several protein tyrosine kinases .'}, {'start':(11, 0), 'end':(11, 12), 'text':'However , the mechanism for this oncogenic activation has not been defined .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 1), 'text':'Recent inferences'}, {'start':(12, 2), 'end':(12, 9), 'text':'drawn from crystallographic and chemical genetic studies suggest'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(12, 10), 'end':(12, 19), 'text':'that ABL and SRC are regulated in a similar fashion'}, {'start':(12, 20), 'end':(12, 27), 'text':'and have highly conserved tertiary structures - .'}]}]}]}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 23), 'text':'Interestingly , mutation of the gatekeeper residue has been noted in the sequence of v-SRC from several independent strains of avian Rous sarcoma virus'}, {'start':(13, 24), 'end':(13, 27), 'text':'( RSV ) ,'}]}, {'start':(13, 28), 'end':(13, 40), 'text':'but the mechanism responsible for cellular transformation was not clearly defined - .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 22), 'text':'On the basis of the strong correlation between substitution of the gatekeeper threonine and oncogenic activation of v-SRC , and on structural considerations'}, {'start':(14, 23), 'end':(14, 33), 'text':'gleaned from our previous studies with dual SRC-ABL kinase inhibitors ,'}]}, {'start':(14, 34), 'end':(14, 35), 'text':'we reasoned'}]}, {'start':(14, 36), 'end':(14, 56), 'text':'that substitution of the gatekeeper threonine residue with bulkier residues would be a common mechanism of activation of tyrosine kinases .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(15, 0), 'end':(15, 5), 'text':'In this study , we show'}, {'start':(15, 6), 'end':(15, 26), 'text':'that the substitution of a bulkier hydro-phobic residue for the gatekeeper threonine in the human tyrosine kinases activates tyrosine phosphorylation .'}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(16, 0), 'end':(16, 17), 'text':'In silico modeling of the native and gatekeeper variants of different kinases and crystallographic analysis of SRC-T341I suggest'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 18), 'end':(16, 31), 'text':'that an isoleucine substitution for the gatekeeper threonine stabilizes a \' hydrophobic spine \''}, {'start':(16, 32), 'end':(16, 44), 'text':'that is a characteristic feature of the active state of several kinases .'}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(17, 0), 'end':(17, 5), 'text':'In support of this hypothesis ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(17, 6), 'end':(17, 7), 'text':'we show'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 8), 'end':(17, 19), 'text':'that disruption of hydrophobic connectivity either pharmacologically or by mutagenesis of residues'}, {'start':(17, 20), 'end':(17, 37), 'text':'constituting the spine can effectively inhibit the kinase activity of the gatekeeper variants of c-ABL and BCR-ABL .'}]}]}]}]}]}]}]}
25	122	{'label':'topic-change', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'RESULTS'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 8), 'text':'Gatekeeper mutations in c-SRC and c-ABL activate the kinase'}, {'start':(2, 0), 'end':(2, 12), 'text':'The gatekeeper residue threonine is found in many tyrosine kinases ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 17), 'text':'It lies in the hinge region between the N and C lobes of the kinase ( ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 18), 'end':(3, 25), 'text':'where it controls access to a hydrophobic pocket'}, {'start':(3, 26), 'end':(3, 37), 'text':'that helps anchor kinase inhibitors to the active site ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 7), 'text':'Because v-SRC and BCR-ABL are already deregulated ,'}, {'start':(4, 8), 'end':(4, 12), 'text':'enzymatically activated protein kinases ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 13), 'end':(4, 31), 'text':'we examined the effect of mutation of the gatekeeper residue on the kinase function of c-SRC and c-ABL isoform1b'}, {'start':(4, 32), 'end':(4, 40), 'text':'( the gatekeeper threonine is residue 334 ) .'}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 15), 'text':'Transient expression in human embryonic kidney cells ( HEK293T ) of C-terminally His tagged T334I ,'}, {'start':(5, 16), 'end':(5, 33), 'text':'T334A and G2A c ABL mutants revealed elevated kinase activity as compared to native c-ABL ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 7), 'text':'The myristoylation defective G2A mutant of c-ABL ,'}, {'start':(6, 8), 'end':(6, 13), 'text':'which activates the c-ABL kinase ,'}]}, {'start':(6, 14), 'end':(6, 23), 'text':'was included as a positive control for kinase activation .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 15), 'text':'The T334I variant induced equivalent levels of total cellular phosphotyrosine in cell lysates as BCR-ABL ,'}, {'start':(7, 16), 'end':(7, 26), 'text':'whereas T334A and G2A substitutions had weaker effects ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(8, 0), 'end':(8, 9), 'text':'After purification of c-ABL and its variants by nickel-resin ,'}, {'start':(8, 10), 'end':(8, 18), 'text':'we likewise observed increased autophosphorylation of ABL variants ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 19), 'end':(8, 20), 'text':'with T334I'}, {'start':(8, 21), 'end':(8, 29), 'text':'showing the greatest degree of phosphotyrosine ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 3), 'text':'Similarly , we found'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 4), 'end':(9, 17), 'text':'that substitution of isoleucine and methionine at the homologous gatekeeper threonine residue in c-SRC'}, {'start':(9, 18), 'end':(9, 27), 'text':'( T341 ) induced high levels of total cellular phosphotyrosine'}]}, {'start':(9, 28), 'end':(9, 32), 'text':'and increased tyrosine autophosphorylation ;'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 33), 'end':(9, 35), 'text':'methionine substitution ,'}, {'start':(9, 36), 'end':(9, 40), 'text':'which likewise introduces hydophobicity ,'}]}, {'start':(9, 41), 'end':(9, 51), 'text':'has a more dramatic effect than isoleucine substitution ( ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 14), 'text':'To further explore the structural consequences of amino acid substitution at the gatekeeper threonine ,'}, {'start':(10, 15), 'end':(10, 22), 'text':'we created the T341K and T341P mutations .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 1), 'text':'Lysine ,'}, {'start':(11, 2), 'end':(11, 13), 'text':'which introduces a strong positive charge into the enzymatic active site ,'}]}, {'start':(11, 14), 'end':(11, 23), 'text':'caused reduced kinase activation relative to isoleucine and methionine .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 1), 'text':'Proline ,'}, {'start':(12, 2), 'end':(12, 13), 'text':'which is expected to kink the polypeptide backbone at hinge region ,'}]}, {'start':(12, 14), 'end':(12, 19), 'text':'inactivated the enzyme ( ) .'}]}, {'start':(13, 0), 'end':(13, 20), 'text':'These observations demonstrate the sensitivity of the enzyme to amino acid substitutions at the threonine residue of the hinge region .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 9), 'text':'Immuno blotting with phosphospecific antibodies against Tyr416 of c-SRC ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 10), 'end':(14, 21), 'text':'which is phosphorylated in the enzymatically active state , and Tyr527 ,'}, {'start':(14, 22), 'end':(14, 29), 'text':'which is phosphorylated in the inactive state ,'}]}]}, {'start':(14, 30), 'end':(14, 30), 'text':'revealed'}]}, {'start':(14, 31), 'end':(14, 43), 'text':'that several gatekeeper variants of SRC are expressed as catalytically active enzymes .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 8), 'text':'Gatekeeper variants of c-ABL and c-SRC transform BaF3 cells'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(16, 0), 'end':(16, 5), 'text':'Next , we sought to determine'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(16, 6), 'end':(16, 8), 'text':'whether kinase activated'}, {'label':'joint', 'direction':'None', 'children':[{'start':(16, 9), 'end':(16, 19), 'text':'variants of c-ABL and c-SRC would show similar patterns of autophosphorylation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 20), 'end':(16, 33), 'text':'and induce leukemic transformation in BaF3 cells , a cytokine dependent hematopoietic progenitor line'}, {'start':(16, 34), 'end':(16, 48), 'text':'that has been widely used in assays of oncogenicity by activated tyrosine kinases , .'}]}]}]}]}]}, {'start':(17, 0), 'end':(17, 20), 'text':'We expressed gatekeeper mutants and other variants of c-ABL and c-SRC in BaF3 cells by retroviral transduction and puromycin selection .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 27), 'text':'Immuno blotting of total cell protein lysates and purified c-ABL and c-SRC showed a comparable pattern of kinase activation as HEK293T cells for all variants except c-SRC-G2A ,'}, {'start':(18, 28), 'end':(18, 43), 'text':'which showed partial kinase activation in HEK293T cells but not in BaF3 cells ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 12), 'text':'Expression of BCR-ABL and activated PDGFRB , PDGFRA , FMS like tyrosine kinase-3'}, {'start':(19, 13), 'end':(19, 25), 'text':'( FLT3 ) , EGFR and Janus kinase-2 ( JAK2 ) induces interleukin-3'}]}, {'start':(19, 26), 'end':(19, 35), 'text':'( IL-3 ) - independent proliferation of BaF3 cells ,'}]}, {'start':(19, 36), 'end':(19, 47), 'text':'which correlates tightly but not absolutely with malignant transformation , - .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 4), 'text':'We therefore tested BaF3 cells'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 5), 'end':(20, 12), 'text':'expressing c-ABL and c-SRC variants for their capacity'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(20, 13), 'end':(20, 16), 'text':'to survive and proliferate'}, {'start':(20, 17), 'end':(20, 24), 'text':'when cultured in the absence of IL-3 .'}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 9), 'text':'Like BCR-ABL , c-ABL-T334I supported robust survival in short-term assays'}, {'start':(21, 10), 'end':(21, 26), 'text':'( online ) and rapid IL-3-independent proliferation of BaF3 cells in prolonged cell culture ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 16), 'text':'In contrast , cells expressing the weakly activated c-ABL variants T334A and G2A or overexpressing native c-ABL'}, {'start':(22, 17), 'end':(22, 24), 'text':'showed no detectable enhanced survival or proliferation .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(23, 0), 'end':(23, 0), 'text':'Cells'}, {'label':'joint', 'direction':'None', 'children':[{'start':(23, 1), 'end':(23, 22), 'text':'expressing the activated c-SRC variants T341I , T341M , T341K , T381K and Y530F demonstrated only modest degrees of survival ( )'}, {'start':(23, 23), 'end':(23, 35), 'text':'and delayed IL-3-independent cell growth after 10 d of culture ( ) .'}]}]}, {'start':(24, 0), 'end':(24, 10), 'text':'The c-SRC-G2A and c-SRC-T341A cells showed neither survival nor proliferation .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(25, 0), 'end':(25, 6), 'text':'Taken together with the autophosphorylation data ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(25, 7), 'end':(25, 22), 'text':'these results demonstrate a correlation between the level of kinase activation and cellular transformation for c-ABL'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(25, 23), 'end':(25, 25), 'text':'and further suggest'}, {'start':(25, 26), 'end':(25, 42), 'text':'that c-ABL is more effective at transforming this hematopoietic cell line than activated variants of SRC .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 14), 'text':'The longer latency of transformation by SRC kinase variants may be due to the fact'}, {'label':'joint', 'direction':'None', 'children':[{'start':(26, 15), 'end':(26, 24), 'text':'that activated SRC kinase alone is not sufficient for transformation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 25), 'end':(26, 32), 'text':'and may require additional epigenetic or genetic alterations'}, {'start':(26, 33), 'end':(26, 38), 'text':'to transform the BaF3 cells .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(27, 0), 'end':(27, 21), 'text':'To determine whether the in vitro assays of IL-3-independent cell survival and proliferation correlated with the development of leukemia in vivo ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 22), 'end':(27, 25), 'text':'we injected BaF3 cells'}, {'label':'joint', 'direction':'None', 'children':[{'start':(27, 26), 'end':(27, 37), 'text':'expressing the c-ABL and c-SRC variants into syngenic Balb and c mice'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 38), 'end':(27, 47), 'text':'and observed for leukemia induction , with BCR-ABL-expressing BaF3 cells'}, {'start':(27, 48), 'end':(27, 52), 'text':'serving as a control .'}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(28, 0), 'end':(28, 0), 'text':'Mice'}, {'start':(28, 1), 'end':(28, 19), 'text':'injected with c-ABL-T334I or BCR-ABL-transformed BaF3 cells died within 4 weeks with peripheral blood leukocytosis and massive splenomegaly .'}]}]}, {'start':(29, 0), 'end':(29, 16), 'text':'In contrast , none of the other variants of c-ABL or c-SRC developed leukemia ( ) .'}]}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(30, 0), 'end':(30, 2), 'text':'These data demonstrate'}, {'start':(30, 3), 'end':(30, 21), 'text':'that mutation at the gatekeeper threonine can activate the intrinsic tyrosine kinase activity of both c-ABL and c-SRC ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 22), 'end':(30, 33), 'text':'but only activated variants of c-ABL induce leukemia in BaF3 cells ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 34), 'end':(30, 39), 'text':'consistent with a long standing observation'}, {'start':(30, 40), 'end':(30, 49), 'text':'that activated SRC is ineffective at transforming BaF3 cells .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(31, 0), 'end':(31, 7), 'text':'Gatekeeper mutation in receptor tyrosine kinases is activating'}, {'label':'joint', 'direction':'None', 'children':[{'start':(32, 0), 'end':(32, 26), 'text':'Transient expression of the receptor tyrosine kinase PDGFRB and its gatekeeper mutation variants ( T681A , T681I and T681M ) in HEK293T cells showed enhanced kinase autophosphorylation'}, {'start':(32, 27), 'end':(32, 35), 'text':'and increased tyrosine phosphorylation of total cellular protein .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 17), 'text':'Like the c-SRC kinase , introduction of the methionine residue ( PDGFRB-T681M ) generated the most active kinase'}, {'start':(33, 18), 'end':(33, 21), 'text':'( online ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 12), 'text':'For PDGFRA , only the T674M variant was associated with kinase activation ,'}, {'start':(34, 13), 'end':(34, 22), 'text':'as demonstrated by autophosphorylation of purified protein ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 16), 'text':'For unknown reasons , we were unable to achieve adequate expression of EGFR in HEK293T cells .'}, {'start':(36, 0), 'end':(36, 11), 'text':'We next expressed these receptor tyrosine kinase mutants in BaF3 cells .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(37, 0), 'end':(37, 34), 'text':'Immunoblotting of total cell lysates and partially purified proteins showed kinase activation for each of the gatekeeper variants of PDGFRB ( T681A , T681I and T681M ; ) , PDGFRA ( T674I and T674M ;'}, {'start':(37, 35), 'end':(37, 46), 'text':') and EGFR ( T790I , T790M and L858R ; ) .'}]}]}]}]}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(38, 0), 'end':(38, 9), 'text':'For these experiments , EGFR-L858R served as a control ,'}, {'start':(38, 10), 'end':(38, 24), 'text':'because EGFR activation and BaF3 cell transformation has been described previously for this mutation .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(39, 0), 'end':(39, 7), 'text':'The results of these gatekeeper mutagenesis studies revealed'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 8), 'end':(39, 31), 'text':'that , like c-ABL and c-SRC , PDGFRB is maximally activated by the substitution with bulkier residues ( isoleucine and methionine ) and more'}, {'start':(39, 32), 'end':(39, 36), 'text':'modestly activated by alanine substitution'}]}, {'start':(39, 37), 'end':(39, 39), 'text':'( ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 40), 'end':(39, 54), 'text':'whereas PDGFRA and EGFR can be activated only by the substitution with isoleucine or methionine'}, {'start':(39, 55), 'end':(39, 70), 'text':'but are tolerant of substitution with smaller side chain substitutions such as alanine ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(40, 0), 'end':(40, 4), 'text':'Unlike BCR-ABL or c-ABL-T334I ,'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(40, 5), 'end':(40, 8), 'text':'none of the receptors'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 9), 'end':(40, 19), 'text':'bearing gatekeeper mutations supported short term IL-3-free survival in BaF3 cells'}, {'start':(40, 20), 'end':(40, 23), 'text':'( online ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(41, 0), 'end':(41, 6), 'text':'Like c-SRC-T341M / I , BaF3 cells'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(41, 7), 'end':(41, 8), 'text':'carrying receptors'}, {'start':(41, 9), 'end':(41, 39), 'text':'bearing the gatekeeper variants PDGFRB-T681I , PDGFRB-T681M ; PDGFRA-T674I , PDGFRA-T674M ; EGFR-T790I , EGFR-T790M and EGFR-L858R showed delayed but robust growth of BaF3 cells after 9-10 d ( ) .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(42, 0), 'end':(42, 15), 'text':'The longer latency of transformation by these receptor kinase variants may be due to the fact'}, {'label':'joint', 'direction':'None', 'children':[{'start':(42, 16), 'end':(42, 25), 'text':'that the activated kinase alone is not sufficient for transformation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(42, 26), 'end':(42, 33), 'text':'and may require additional epigenetic or genetic alterations'}, {'start':(42, 34), 'end':(42, 39), 'text':'to transform the BaF3 cells .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(43, 0), 'end':(43, 2), 'text':'These data demonstrate'}, {'label':'joint', 'direction':'None', 'children':[{'start':(43, 3), 'end':(43, 14), 'text':'that the gatekeeper mutations activate the kinase activity in receptor tyrosine kinases'}, {'start':(43, 15), 'end':(43, 35), 'text':'and can transform the cytokine dependent cell line BaF3 , although with longer latency than for activated variants of c-ABL .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 7), 'text':'A hydrophobic spine is assembled during kinase activation'}, {'start':(45, 0), 'end':(45, 23), 'text':'Crystal structures of protein kinases in their active and inactive conformations have provided a general understanding of their regulation via intramolecular autoregulatory interactions .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 0), 'end':(46, 18), 'text':'Typically , activation involves changes in the position and orientation of the activation loop and the catalytic c-helix .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 0), 'end':(47, 17), 'text':'A surface comparison of active kinase structures has revealed a network of highly conserved hydrophobic or amino-aromatic interactions'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 18), 'end':(47, 22), 'text':'called the hydrophobic spine ,'}, {'start':(47, 23), 'end':(47, 29), 'text':'which stabilizes the active kinase conformation .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 0), 'end':(48, 17), 'text':'In ABL kinase , the spine comprises four residues , Leu320 , Met309 , Phe401 and His380 ,'}, {'start':(48, 18), 'end':(48, 42), 'text':'which form a chain of hydrophobic interactions from the N lobe via the active site to the Tyr412 of the activation loop ( ) .'}]}, {'start':(49, 0), 'end':(49, 10), 'text':'These interactions are disrupted in the inactive state ( ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(50, 0), 'end':(50, 13), 'text':'The gatekeeper residue Thr334 is situated near the tip of the hydrophobic spine .'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(51, 0), 'end':(51, 3), 'text':'Our modeling analysis suggests'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(51, 4), 'end':(51, 18), 'text':'that substitution of a bulkier hydrophobic residue at this position would stabilize the active state'}, {'start':(51, 19), 'end':(51, 23), 'text':'by strengthening the spine .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 9), 'text':'In our model , Leu403 serves as a bipositional switch'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 10), 'end':(52, 20), 'text':'that positions Asp400 of the DFG motif in the correct orientation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 21), 'end':(52, 23), 'text':'to enable catalysis'}, {'start':(52, 24), 'end':(52, 27), 'text':'( online ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 0), 'end':(53, 15), 'text':'In the active state the backbone of Leu403 coordinates Arg381 of the catalytic HRD motif ,'}, {'start':(53, 16), 'end':(53, 35), 'text':'whereas in the inactive state the sidechain of Leu403 stabilizes Phe401 in the catalytically quiescent \' DFG-out \' conformation .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 0), 'end':(54, 26), 'text':'Furthermore , computational modeling of the published structures of SRC and EGFR revealed similar hydrophobic interactions in SRC ( online ) and EGFR ( online ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 27), 'end':(54, 38), 'text':'where the gatekeeper residue sits at the top of the spine ,'}, {'start':(54, 39), 'end':(54, 43), 'text':'stabilizing the active state .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 0), 'end':(55, 26), 'text':'The active SRC and EGFR kinases maintain a hydrophobic spine from the gatekeeper threonine to Tyr419 and Tyr869 of the activation loop , respectively ( ) .'}, {'start':(56, 0), 'end':(56, 10), 'text':'These interactions are disrupted in the inactive state ( ) .'}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(57, 0), 'end':(57, 3), 'text':'As in ABL ,'}, {'start':(57, 4), 'end':(57, 20), 'text':'Leu410 of SRC and Leu858 of EGFR serve as a bipositional switch for kinase regulation , .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(58, 0), 'end':(58, 6), 'text':'Altogether , these in silico analyses suggest'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(58, 7), 'end':(58, 16), 'text':'that gatekeeper mutants stabilize the active state of the kinase'}, {'start':(58, 17), 'end':(58, 23), 'text':'by contributing to the hydrophobic spine .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(59, 0), 'end':(59, 4), 'text':'SRC-T341I adopts an active conformation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 0), 'end':(60, 14), 'text':'We crystallized the isoleucine substitution of the gatekeeper residue of the chicken c-SRC kinase domain'}, {'label':'joint', 'direction':'None', 'children':[{'start':(60, 15), 'end':(60, 22), 'text':'( residues 251-533 ) in complex with ATPgammaS'}, {'start':(60, 23), 'end':(60, 33), 'text':'and determined the structure to a resolution of 2.0 A .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(61, 0), 'end':(61, 13), 'text':'The four molecules present in the asymmetric unit are in virtually identical conformations ;'}, {'start':(61, 14), 'end':(61, 23), 'text':'further discussion focuses on one of these ( ) .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(62, 0), 'end':(62, 16), 'text':'There is well defined electron density for the adenine , ribose and the alpha-phosphate groups of ATPgammaS'}, {'start':(62, 17), 'end':(62, 27), 'text':'and less well defined density for the beta- and gamma-phosphates .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(63, 0), 'end':(63, 10), 'text':'The activation loop is fully ordered and Tyr419 is phosphorylated .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 0), 'end':(64, 19), 'text':'The overall conformation of the c-Src-T341I mutant resembles that of the activation loop phosphorylated Lck ( PDB 1QPC ) ,'}, {'start':(64, 20), 'end':(64, 47), 'text':'where Phe408 of the DFG motif forms contacts with residues His387 and Met317 of the hydrophobic spine , such that the hydrophobic spine is assembled ( ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(65, 0), 'end':(65, 16), 'text':'However , in the inactive state of the SRC kinase conformation , the hydrophobic spine is crippled'}, {'start':(65, 17), 'end':(65, 28), 'text':'and the activation loop is not phosphorylated and extended ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(66, 0), 'end':(66, 6), 'text':'Gatekeeper mutation efficiently organizes the active site'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(67, 0), 'end':(67, 19), 'text':'We compared the structure of the gatekeeper variant of c-SRC with a high-resolution structure of a wild-type SRC family kinase'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(67, 20), 'end':(67, 33), 'text':'-- Lck bound to the ATP analog AMP-PNP , also in the active conformation'}, {'start':(67, 34), 'end':(67, 38), 'text':'( PDB 1QPC ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(68, 0), 'end':(68, 14), 'text':'In both structures , an active-site lysine residue ( SRC Lys298 and Lck Lys273 )'}, {'label':'contrast', 'direction':'None', 'children':[{'start':(68, 15), 'end':(68, 33), 'text':'forms a hydrogen bond with a glutamate residue in helix alphaC ( SRC Glu310 and Lck Glu288 ) ,'}, {'start':(68, 34), 'end':(68, 49), 'text':'but the conformation of the lysine residue is different in the two structures ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(69, 0), 'end':(69, 14), 'text':'In the wild-type Lck , two water molecules are interdigitated between Thr316 and Lys273 ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 15), 'end':(69, 32), 'text':'and the lysine side chain does not form hydrogen bonds with the phosphate groups of the ATP analog'}, {'start':(69, 33), 'end':(69, 49), 'text':'( the closest distance between the lysine nitrogen and a phosphate oxygen is 5.5 A ) .'}]}]}]}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(70, 0), 'end':(70, 25), 'text':'In the SRC structure , the substitution of isoleucine leads to the exclusion of these water molecules and the rearrangement of the lysine side chain ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(70, 26), 'end':(70, 32), 'text':'which packs closely to the isoleucine residue'}, {'start':(70, 33), 'end':(70, 51), 'text':'and forms a hydrogen bond to the alpha-phosphate of the nucleotide ( N-O distance of 3.4 A ) .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(71, 0), 'end':(71, 15), 'text':'The hydrophobic packing of Ile341 and Lys298 seals off the interior of the kinase domain ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(71, 16), 'end':(71, 18), 'text':'thereby excluding water'}, {'start':(71, 19), 'end':(71, 35), 'text':'and potentiating the hydrophobic spine and interaction of Lys298 with ATP relative to the wild-type structure .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(72, 0), 'end':(72, 30), 'text':'A similar orientation of the lysine residue and ATP is seen in the structure of kinases with hydrophobic residues at the gatekeeper position of the insulin receptor kinase ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(73, 0), 'end':(73, 8), 'text':'On the basis of these observations , we infer'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(73, 9), 'end':(73, 15), 'text':'that the T341I mutation activates the kinase'}, {'start':(73, 16), 'end':(73, 28), 'text':'by optimizing the coordination of ATP and by stabilizing the hydrophobic spine .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(74, 0), 'end':(74, 7), 'text':'Mutagenesis of the hydrophobic spine causes kinase inactivation'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(75, 0), 'end':(75, 2), 'text':'Our model predicts'}, {'start':(75, 3), 'end':(75, 14), 'text':'that kinase activity is dependent on assembly of the hydrophobic spine .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(76, 0), 'end':(76, 3), 'text':'To test this ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(76, 4), 'end':(76, 8), 'text':'we mutated all four residues'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(76, 9), 'end':(76, 16), 'text':'that constitute the spine in the ABL kinase'}, {'start':(76, 17), 'end':(76, 25), 'text':'( Leu320 , Met309 , Phe401 and Thr334 )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(76, 26), 'end':(76, 34), 'text':'to glycine and analyzed kinase activity in a cell'}, {'start':(76, 35), 'end':(76, 37), 'text':'based assay .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(77, 0), 'end':(77, 11), 'text':'M309G , F401G and T334G completely abrogated kinase activity ( ) ,'}, {'start':(77, 12), 'end':(77, 23), 'text':'whereas L320G showed a decreased level of phosphorylation relative to ABL-T334I .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(78, 0), 'end':(78, 25), 'text':'Molecular modeling of the L320G revealed only a modest effect on spine assembly , consistent with the modestly reduced kinase activation of ABL-T315I ( ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(78, 26), 'end':(78, 39), 'text':'whereas , M309G and F401G mutations completely disrupted the assembly of the spine ,'}, {'start':(78, 40), 'end':(78, 45), 'text':'inactivating the kinase ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(79, 0), 'end':(79, 8), 'text':'Similarly , double or triple mutations of the residues'}, {'start':(79, 9), 'end':(79, 22), 'text':'that disrupted the spine assembly also resulted in an inactive kinase ( ) .'}]}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(80, 0), 'end':(80, 3), 'text':'These mutagenesis data suggest'}, {'start':(80, 4), 'end':(80, 22), 'text':'that the hydrophobic spine is a key structural element of the enzymatically active conformation of the ABL kinase .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(81, 0), 'end':(81, 7), 'text':'Compound 14 inhibits the gatekeeper variants of BCR-ABL'}, {'label':'background', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(82, 0), 'end':(82, 2), 'text':'Given our hypothesis'}, {'start':(82, 3), 'end':(82, 10), 'text':'that gatekeeper mutations stabilize the hydrophobic spine ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(82, 11), 'end':(82, 12), 'text':'we reasoned'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(82, 13), 'end':(82, 17), 'text':'that a small-molecule ATP-competitive inhibitor'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(82, 18), 'end':(82, 29), 'text':'that can disrupt the hydrophobic spine may achieve the necessary binding affinity'}, {'start':(82, 30), 'end':(82, 39), 'text':'to successfully inhibit the kinase activity of gatekeeper mutants .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(83, 0), 'end':(83, 7), 'text':'We performed structural alignment of the ABL kinase'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(83, 8), 'end':(83, 11), 'text':'crystallized with different inhibitors'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(83, 12), 'end':(83, 15), 'text':'to identify an inhibitor'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(83, 16), 'end':(83, 20), 'text':'that can dismantle the spine'}, {'start':(83, 21), 'end':(83, 29), 'text':'without any physical interaction with the activation loop .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(84, 0), 'end':(84, 7), 'text':'By this analysis , we identified compound 14'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(84, 8), 'end':(84, 17), 'text':'as being able to efficiently compete for the spine residues'}, {'start':(84, 18), 'end':(84, 27), 'text':'without directly affecting the mobility of the activation loop .'}]}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(85, 0), 'end':(85, 11), 'text':'Compound 14 was generated by a rational \' hybrid design \' approach'}, {'start':(85, 12), 'end':(85, 26), 'text':'by appending a trifluoromethyl group to the parent inhibitor PD166326 ( ref ; ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(86, 0), 'end':(86, 13), 'text':'Compound 14 , like imatinib , disrupts the assembly of the hydrophobic spine ,'}, {'start':(86, 14), 'end':(86, 25), 'text':'thereby locking the kinase in an inactive \' DFG-out \' conformation .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(87, 0), 'end':(87, 16), 'text':'The shape of compound 14 resembles that of the core of imatinib , with the key difference'}, {'start':(87, 17), 'end':(87, 32), 'text':'that the hydrophilic methyl-piperazine group in imatinib is replaced with the more hydrophobic trifluoromethyl moiety .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(88, 0), 'end':(88, 3), 'text':'The structure also suggests'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(88, 4), 'end':(88, 17), 'text':'that the trifluoromethylbenzamide ring of compound 14 competes for Phe401 of the DFG motif'}, {'start':(88, 18), 'end':(88, 30), 'text':'without having any direct physical interaction with the activation loop ( ) .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(89, 0), 'end':(89, 3), 'text':'Therefore , we reasoned'}, {'start':(89, 4), 'end':(89, 26), 'text':'that compound 14 may , at a higher concentration , efficiently inhibit the gatekeeper mutant ABL T315I by destabilizing the active state .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(90, 0), 'end':(90, 12), 'text':'Additionally , the trifluoromethyl group of compound 14 fits into a hydrophobic cavity'}, {'start':(90, 13), 'end':(90, 24), 'text':'created by the disruption of the spine residues Phe401 and His387 ,'}]}, {'start':(90, 25), 'end':(90, 33), 'text':'and this may provide extra anchorage for affinity .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(91, 0), 'end':(91, 11), 'text':'We tested compound 14 and the parent inhibitor PD166326 for their ability'}, {'start':(91, 12), 'end':(91, 22), 'text':'to inhibit native and gatekeeper variants of ABL and BCR-ABL .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(92, 0), 'end':(92, 14), 'text':'Compound 14 inhibited c-ABL-T334I , BCR-ABL and BCR-ABL-T315I variants with a 50 % inhibitory concentration'}, {'start':(92, 15), 'end':(92, 32), 'text':'( IC 50 ) of 0.25 muM , 0.09 muM and 0.590 muM , respectively ( ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(93, 0), 'end':(93, 15), 'text':'In contrast , PD166326 barely inhibited c-ABL-T334I , with an IC 50 of 8.0 muM ,'}, {'start':(93, 16), 'end':(93, 29), 'text':'and showed a complete lack of activity up to 10 muM against BCR-ABL-T315I .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(94, 0), 'end':(94, 18), 'text':'Similarly , imatinib and nilotinib has been shown to be completely resistant against the gatekeeper mutant , , .'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(95, 0), 'end':(95, 2), 'text':'These results demonstrate'}, {'label':'joint', 'direction':'None', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(95, 3), 'end':(95, 10), 'text':'that the gatekeeper mutants stabilize the active state'}, {'start':(95, 11), 'end':(95, 16), 'text':'by potentiating the hydrophobic spine ,'}]}, {'start':(95, 17), 'end':(95, 32), 'text':'and disruption of the spine by a small-molecule inhibitor can efficiently inhibit the gatekeeper mutant .'}]}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(96, 0), 'end':(96, 8), 'text':'Although imatinib and nilotinib disrupt the hydrophobic spine ,'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(96, 9), 'end':(96, 10), 'text':'the fact'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(96, 11), 'end':(96, 31), 'text':'that they fail to show any activity against the gatekeeper mutant may be due to the requirement of higher free energy'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(96, 32), 'end':(96, 36), 'text':'to destabilize the active state'}, {'start':(96, 37), 'end':(96, 46), 'text':'imposed by their physical interactions with the activation loop .'}]}]}]}]}]}]}
0	1	{'start':(0, 0), 'end':(0, 9), 'text':'Activation of tyrosine kinases by mutation of the gatekeeper threonine'}
206	207	{'start':(0, 0), 'end':(0, 1), 'text':'Supplementary Material'}
1	7	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 1), 'text':'Protein kinases'}, {'start':(0, 2), 'end':(0, 21), 'text':'targeted by small-molecule inhibitors develop resistance through mutation of the \' gatekeeper \' threonine residue of the active site .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(1, 0), 'end':(1, 2), 'text':'Here we show'}, {'label':'joint', 'direction':'None', 'children':[{'start':(1, 3), 'end':(1, 23), 'text':'that the gatekeeper mutation in the cellular forms of c-ABL , c-SRC , platelet derived growth factor receptor-alpha and -beta ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(1, 24), 'end':(1, 31), 'text':'and epidermal growth factor receptor activates the kinase'}, {'start':(1, 32), 'end':(1, 39), 'text':'and promotes malignant transformation of BaF3 cells .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(2, 0), 'end':(2, 2), 'text':'Structural analysis reveals'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 3), 'end':(2, 8), 'text':'that a network of hydrophobic interactions'}, {'start':(2, 9), 'end':(2, 13), 'text':'-- the hydrophobic spine --'}]}, {'start':(2, 14), 'end':(2, 26), 'text':'characteristic of the active kinase conformation is stabilized by the gatekeeper substitution .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(3, 0), 'end':(3, 5), 'text':'Substitution of glycine for the residues'}, {'label':'joint', 'direction':'None', 'children':[{'start':(3, 6), 'end':(3, 12), 'text':'constituting the spine disrupts the hydrophobic connectivity'}, {'start':(3, 13), 'end':(3, 17), 'text':'and inactivates the kinase .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 4), 'text':'Furthermore , a small-molecule inhibitor'}, {'start':(4, 5), 'end':(4, 11), 'text':'that maximizes complementarity with the dismantled spine'}]}, {'start':(4, 12), 'end':(4, 22), 'text':'( compound 14 ) inhibits the gatekeeper mutation of BCR-ABL-T315I .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 2), 'text':'These results demonstrate'}, {'label':'joint', 'direction':'None', 'children':[{'start':(5, 3), 'end':(5, 17), 'text':'that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 18), 'end':(5, 21), 'text':'and provide structural insights'}, {'start':(5, 22), 'end':(5, 30), 'text':'to guide the development of next generation inhibitors .'}]}]}]}]}]}
122	144	{'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'DISCUSSION'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 11), 'text':'Substitution of the gatekeeper threonine residue by isoleucine in the BCR-ABL oncoprotein'}, {'start':(1, 12), 'end':(1, 25), 'text':'( T315I ) was the first resistance mutation noted in imatinib treated patients ,'}]}, {'start':(1, 26), 'end':(1, 43), 'text':'and mutation in the homologous residue has emerged as a common mechanism of resistance for numerous kinases .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(2, 0), 'end':(2, 3), 'text':'Structural studies have shown'}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 4), 'end':(2, 12), 'text':'that this threonine stabilizes imatinib binding through hydrogen-bond interactions'}, {'label':'cause', 'direction':'LeftToRight', 'children':[{'start':(2, 13), 'end':(2, 25), 'text':'and regulates access to a deep hydrophobic pocket in the active site ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 26), 'end':(2, 30), 'text':'thus providing a compelling reason'}, {'start':(2, 31), 'end':(2, 42), 'text':'why Rstitution should mediate drug resistance via a steric mechanism alone .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 41), 'text':'However , the identification of T315I in a significant cohort of CML patients with primary imatinib resistance , , the association of germline mutations in the gatekeeper residue of EGFR in familial lung cancer and the historical identification of gatekeeper residue mutations'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 42), 'end':(3, 55), 'text':'in transforming isolates of the v-SRC viral oncoprotein imply a role for this mutation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 56), 'end':(3, 58), 'text':'in promoting malignancy'}, {'start':(3, 59), 'end':(3, 64), 'text':'that has hitherto been unexplained .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(4, 0), 'end':(4, 5), 'text':'In this study , we demonstrate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 6), 'end':(4, 12), 'text':'that the highly conserved threonine gatekeeper residue'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 13), 'end':(4, 30), 'text':'that lies within the hinge region of the enzymatic cleft of many kinases represents a crucial structural feature'}, {'start':(4, 31), 'end':(4, 36), 'text':'whose mutation promotes kinase activation .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 2), 'text':'Our data demonstrate'}, {'label':'joint', 'direction':'None', 'children':[{'start':(5, 3), 'end':(5, 11), 'text':'that threonine mutation is sufficient to activate kinase activity'}, {'start':(5, 12), 'end':(5, 23), 'text':'and transforming function for several native nonreceptor and receptor tyrosine kinases .'}]}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(6, 0), 'end':(6, 0), 'text':'Evidence'}, {'start':(6, 1), 'end':(6, 23), 'text':'that the T315I variant of BCR-ABL has higher oncogenic penetrance in in vitro models supports a direct role in disease pathogenesis , .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 22), 'text':'However , the enhanced oncogenicity has been attributed to increased tyrosine phosphorylation at Tyr257 of BCR-ABL , rather than increased kinase activity ,'}, {'label':'cause', 'direction':'LeftToRight', 'children':[{'start':(7, 23), 'end':(7, 34), 'text':'which may be difficult to discern within the context of BCR-ABL ,'}, {'start':(7, 35), 'end':(7, 42), 'text':'because of its high intrinsic kinase activity .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 6), 'text':'Additionally , the increased binding of ATP'}, {'start':(8, 7), 'end':(8, 16), 'text':'demonstrated by the gatekeeper mutants of ABL and EGFR ,'}]}, {'start':(8, 17), 'end':(8, 26), 'text':'may further contribute to increased phosphorylation of cellular subtrates .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 8), 'text':'Biochemical and structural analyses of protein kinases have revealed'}, {'start':(9, 9), 'end':(9, 23), 'text':'that a complex set of conformational mechanisms regulates the catalytically active and quiescent states .'}]}, {'start':(10, 0), 'end':(10, 40), 'text':'Conformational dynamics of the activation loop and the conserved C helix contribute to formation of an ion pair between a crucial lysine residue within the beta3 strand of the N lobe and a crucial glutamate residue within the C helix .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(11, 0), 'end':(11, 4), 'text':'Ultimately , protein dynamics ensures'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 5), 'end':(11, 9), 'text':'that a conserved DFG motif'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 10), 'end':(11, 22), 'text':'lying at the tip of the activation loop is oriented in a manner'}, {'start':(11, 23), 'end':(11, 31), 'text':'that allows coordinated binding of magnesium and ATP .'}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(12, 0), 'end':(12, 10), 'text':'In adopting the enzymatically competent \' DFG in \' conformation ,'}, {'start':(12, 11), 'end':(12, 26), 'text':'the N lobe and C lobe move toward one another to accommodate these structural changes .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 4), 'text':'Our study supports a model'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 5), 'end':(13, 13), 'text':'whereby the hydrophobic spine serves as a structural element'}, {'start':(13, 14), 'end':(13, 20), 'text':'linking the N and C lobes .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 17), 'text':'The gatekeeper residue , by virtue of its location , stabilizes the spine in the active conformation ,'}, {'start':(14, 18), 'end':(14, 37), 'text':'whereas the inactive state is stabilized by autoinhibitory regulatory domain interactions and by association with negative regulatory proteins , .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(15, 0), 'end':(15, 0), 'text':'Mutations'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 1), 'end':(15, 9), 'text':'that disrupt this autoinhibition promote enzymatically active kinase conformations'}, {'start':(15, 10), 'end':(15, 18), 'text':'that are intrinsically resistant to imatinib binding , .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(16, 0), 'end':(16, 26), 'text':'Although direct steric hindrance has been invoked to explain the resistance of BCR-ABL-T315I , KIT-T670I , PDGFRA-T674I and EGFR-T790M to kinase inhibitor binding , , , ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(16, 27), 'end':(16, 29), 'text':'our data suggest'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(16, 30), 'end':(16, 45), 'text':'that threonine mutation acts as well to promote the assembly of an enzymatically active kinase conformation'}, {'start':(16, 46), 'end':(16, 51), 'text':'by stabilizing the hydrophobic spine .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(17, 0), 'end':(17, 1), 'text':'We anticipate'}, {'start':(17, 2), 'end':(17, 12), 'text':'that this regulatory mechanism is conserved across the kinase family .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'start':(18, 0), 'end':(18, 18), 'text':'Substitution of the gatekeeper threonine residue with alanine , a smaller hydrophobic residue , likewise causes kinase activation ,'}, {'start':(18, 19), 'end':(18, 28), 'text':'but less robustly than substituton with isoleucine or methionine .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 2), 'text':'A recent report'}, {'start':(19, 3), 'end':(19, 17), 'text':'using hydrogen-exchange ( HX ) studies of the native and gatekeeper mutated ERK2-Q103A kinase demonstrated'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 18), 'end':(19, 30), 'text':'that substitutions of smaller hydrophobic residues create a cavity within the hydrophobic cluster'}, {'label':'joint', 'direction':'None', 'children':[{'start':(19, 31), 'end':(19, 35), 'text':'that destabilizes the autoinhibited state'}, {'label':'joint', 'direction':'None', 'children':[{'start':(19, 36), 'end':(19, 47), 'text':'and increases the flexibility of the DFG motif and activation loop ,'}, {'start':(19, 48), 'end':(19, 61), 'text':'and increased flexibility of the activation segment would be expected to favor autophosphorylation .'}]}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 2), 'text':'Given our data'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(20, 3), 'end':(20, 3), 'text':'showing'}, {'start':(20, 4), 'end':(20, 18), 'text':'that gatekeeper residue mutations cause kinase activation in several receptor and nonreceptor tyrosine kinases ,'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(20, 19), 'end':(20, 20), 'text':'we speculate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 21), 'end':(20, 31), 'text':'that this phenomenon may be a generic feature of kinase regulation'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(20, 32), 'end':(20, 35), 'text':'that helps to explain'}, {'start':(20, 36), 'end':(20, 47), 'text':'why this class of mutation has been observed in drug-naive patients .'}]}]}]}]}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 5), 'text':'In future drug design , structures'}, {'start':(21, 6), 'end':(21, 16), 'text':'that maximize complementarity to the dismantled spine should be favored ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 17), 'end':(21, 22), 'text':'as these represent an inhibitor class'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(21, 23), 'end':(21, 25), 'text':'that optimizes specificity'}, {'label':'temporal', 'direction':'None', 'children':[{'start':(21, 26), 'end':(21, 30), 'text':'by recognizing inactive kinase conformations'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 31), 'end':(21, 39), 'text':'while gaining sufficient affinity to be active against kinases'}, {'start':(21, 40), 'end':(21, 47), 'text':'that carry mutations at the gatekeeper residue .'}]}]}]}]}]}]}]}]}]}
207	209	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 1), 'text':'Supp .'}, {'start':(1, 0), 'end':(1, 0), 'text':'File'}]}
144	206	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'METHODS'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 1), 'text':'Plasmid constructs'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 5), 'text':'We cloned full-length c-ABL isoform Ib'}, {'start':(2, 6), 'end':(2, 19), 'text':'by replacing the BCR portion of BCR-ABL with the N terminus of c-ABL-Ib .'}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(3, 0), 'end':(3, 12), 'text':'A 0.6-kb N-terminal DNA fragment of c-ABL-Ib ( starting with initiation codon ATG'}, {'start':(3, 13), 'end':(3, 25), 'text':'and ending with the amino acid residue G163 of the SH2 domain )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 26), 'end':(3, 29), 'text':'was amplified by PCR'}, {'start':(3, 30), 'end':(3, 42), 'text':'using gene specific primers ( online ) and cDNA from HEK293T cells .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 8), 'text':'This 0.6-kb fragment was digested with KpnI and BamHI'}, {'start':(4, 9), 'end':(4, 17), 'text':'and ligated to BamHI and KpnI digested pEYKBA ,'}]}, {'start':(4, 18), 'end':(4, 20), 'text':'yielding pEYKABL-Ib .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 7), 'text':'Because pEYK vectors lack a selectable marker ,'}, {'start':(5, 8), 'end':(5, 28), 'text':'we constructed two different selectable expression vectors ( pOP-Ires-GFP-Puro and pOP-Ires-RFP-Puro ) for stable expression of transgenes in mammalian cells .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(6, 0), 'end':(6, 3), 'text':'To construct pOP-Ires-GFP-Puro ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 4), 'end':(6, 20), 'text':'pEYK3 .1 was digested with EcoR I and DNA ends were filled in by Klenow polymerase ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 21), 'end':(6, 26), 'text':'followed by ligation with DNA fragments'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 27), 'end':(6, 28), 'text':'containing Ires-GFP'}, {'label':'joint', 'direction':'None', 'children':[{'start':(6, 29), 'end':(6, 34), 'text':'( pMSCV-IresGFP was digested with SalI'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 35), 'end':(6, 44), 'text':'and the ends were filled in by Klenow polymerase ,'}, {'start':(6, 45), 'end':(6, 64), 'text':'followed by DNA purification by agarose gel electrophoresis ) and SV40-PURO ( pBABE was digested with Sal1 and MluI ,'}]}, {'start':(6, 65), 'end':(6, 74), 'text':'followed by DNA purification by agarose gel electrophoresis ) .'}]}]}]}]}]}]}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(7, 0), 'end':(7, 3), 'text':'To construct pOP-Ires-RFP-puro ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 4), 'end':(7, 18), 'text':'pOP-Ires-GFP-Puro was digested with SalI and DNA ends were filled by the Klenow polymerase ,'}, {'start':(7, 19), 'end':(7, 25), 'text':'followed by digestion with Bam H1 .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(8, 0), 'end':(8, 4), 'text':'The vector backbone was purified'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 5), 'end':(8, 10), 'text':'and ligated to a DNA fragment'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 11), 'end':(8, 13), 'text':'containing Ires-RFP ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 14), 'end':(8, 19), 'text':'which was derived from the pIRES2'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(8, 20), 'end':(8, 24), 'text':'DsRed ( Clontech ) vector'}, {'start':(8, 25), 'end':(8, 32), 'text':'by digesting it with NotI and BglII .'}]}]}]}]}]}]}]}, {'start':(9, 0), 'end':(9, 5), 'text':'pEYKABL-Ib was digested with EcoRI .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 2), 'text':'The DNA fragment'}, {'start':(10, 3), 'end':(10, 4), 'text':'containing ABL-Ib'}]}, {'start':(10, 5), 'end':(10, 11), 'text':'was purified from pEYKABL-Ib by EcoRI digestion'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 12), 'end':(10, 18), 'text':'and ligated to EcoRI digested pOP-Ires-GFP-Puro ,'}, {'start':(10, 19), 'end':(10, 21), 'text':'yielding pOPABL-Ib .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 18), 'text':'A six-histidine tag was attached at the C terminus of pOPABL-Ib by PCR ( primers are listed in )'}, {'start':(11, 19), 'end':(11, 27), 'text':'using the Quickchange mutagenesis kit ( Stratagene ) .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 23), 'text':'We found no difference in the activity of the histidine tagged and native versions of ABL and SRC or their gatekeeper variants ( data'}, {'start':(12, 24), 'end':(12, 27), 'text':'not shown ) ,'}]}, {'start':(12, 28), 'end':(12, 43), 'text':'and therefore the kinase activation observed is unlikely to be influenced by the histidine tag .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 8), 'text':'SRC , PDGFRA and EGFR were cloned by PCR'}, {'start':(13, 9), 'end':(13, 15), 'text':'using Hi-fidelity polymerase ( Roche ) ,'}]}, {'start':(13, 16), 'end':(13, 27), 'text':'gene specific primers ( ) , and cDNA from HEK293T cells .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 6), 'text':'PDGFRB was cloned from total human cDNA'}, {'start':(14, 7), 'end':(14, 11), 'text':'( Clontech ) by PCR'}]}, {'start':(14, 12), 'end':(14, 18), 'text':'using gene specific primers ( ) .'}]}, {'start':(15, 0), 'end':(15, 18), 'text':'These PCR products were cloned into TA cloning vectors pCRXL-TOPO ( Invitrogen ) and pSCB ( Stratagene ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 7), 'text':'c-SRC and PDGFRB were cloned in pCRXL-TOPO vectors'}, {'start':(16, 8), 'end':(16, 13), 'text':'to yield pCRXL-SRC and pCRXL-PDGFRB ,'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(16, 14), 'end':(16, 23), 'text':'whereas PDGFRB and EGFR were cloned into the pSC vector'}, {'start':(16, 24), 'end':(16, 29), 'text':'to yield pSC-EGFR and pSC-PDGFRA .'}]}]}, {'start':(17, 0), 'end':(17, 8), 'text':'Four different clones for each gene were sequenced .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 1), 'text':'The clones'}, {'start':(18, 2), 'end':(18, 15), 'text':'that were devoid of mutations were used for subcloning into pOP expression vectors .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 4), 'text':'The EcoRI fragment of pCRXL-SRC'}, {'start':(19, 5), 'end':(19, 19), 'text':'containing the SRC coding gene was purified and ligated to EcoRI digested pOP-Ires-GFP-Puro vector ,'}]}, {'start':(19, 20), 'end':(19, 22), 'text':'yielding pOP-SRC-Ires-GFP-Puro .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 12), 'text':'Similarly , PDGFRB was cloned into the EcoRI site of the pOP-Ires-GFP-Puro vector'}, {'start':(20, 13), 'end':(20, 17), 'text':'to give rise pOP-PDGFRB-Ires-GFP-Puro .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 8), 'text':'The plasmid pSC-PDGFRA was digested with BamHI and AgeI'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 9), 'end':(21, 12), 'text':'to excise the fragment'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 13), 'end':(21, 17), 'text':'containing the coding region ,'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(21, 18), 'end':(21, 26), 'text':'followed by cloning in pOP-Ires-RFP-Puro at the BamHI site'}, {'start':(21, 27), 'end':(21, 30), 'text':'to yield pOP-PDGFRA-Ires-RFP-Puro .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(22, 0), 'end':(22, 9), 'text':'Finally , pSCEGFR was digested with XhoI and PvuI ;'}, {'label':'joint', 'direction':'None', 'children':[{'start':(22, 10), 'end':(22, 18), 'text':'the DNA fragment was purified and ligated to SalI'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 19), 'end':(22, 22), 'text':'and XhoI digested pOP-Ires-GFP-Puro'}, {'start':(22, 23), 'end':(22, 26), 'text':'to yield pOP-EGFR-Puro .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(23, 0), 'end':(23, 8), 'text':'To construct gatekeeper mutant versions of these kinases ,'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(23, 9), 'end':(23, 9), 'text':'oligonucleotides'}, {'label':'joint', 'direction':'None', 'children':[{'start':(23, 10), 'end':(23, 15), 'text':'overlapping the gatekeeper residue were synthesized'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 16), 'end':(23, 27), 'text':'and used to perform site directed mutagenesis on the respective plasmid template'}, {'start':(23, 28), 'end':(23, 36), 'text':'( Quickchange XL mutagenesis kit ; Stratagene ) .'}]}]}]}]}, {'start':(24, 0), 'end':(24, 6), 'text':'Each mutant was confirmed by sequencing .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 6), 'text':'Cell culture , transfection and retroviral transduction'}, {'label':'joint', 'direction':'None', 'children':[{'start':(26, 0), 'end':(26, 12), 'text':'We carried out HEK293T cell culture , proviral transfection and viral productions ,'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(26, 13), 'end':(26, 16), 'text':'and transduced BaF3 cells'}, {'start':(26, 17), 'end':(26, 20), 'text':'as described previously .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 15), 'text':'At 24 h after transduction , 2.5 mug ml -1 puromycin was added to the media'}, {'start':(27, 16), 'end':(27, 21), 'text':'to select for transduced cells .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(28, 0), 'end':(28, 8), 'text':'After 4-6 d , puromycin resistant cells were counted'}, {'start':(28, 9), 'end':(28, 27), 'text':'and plated at 5,000 cells per well in 96-well plates , with and without IL-3 , in quadruplicate .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(29, 0), 'end':(29, 6), 'text':'Cells were incubated at 37 degreesC ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 7), 'end':(29, 15), 'text':'and the viable cell number was assessed 60 h'}, {'label':'attribution', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 16), 'end':(29, 20), 'text':'later using the WST-1 reagent'}, {'start':(29, 21), 'end':(29, 24), 'text':'( Roche ) ,'}]}, {'start':(29, 25), 'end':(29, 31), 'text':'according to the manufacturer \'s specifications .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 16), 'text':'For prolonged IL-3 survival , 5,000 BaF3 cells were plated in quadruplicate in 96-well plates in RPMI'}, {'start':(30, 17), 'end':(30, 19), 'text':'without IL3 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(31, 0), 'end':(31, 18), 'text':'Cells were incubated at 37 degreesC for 14 d. Numbers of confluent wells were scored as IL-3-independent growth .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 4), 'text':'Balb and c mouse injection'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 5), 'text':'We injected 10 6 BaF3 cells'}, {'start':(33, 6), 'end':(33, 23), 'text':'expressing c-SRC , c-ABL and gatekeeper variants intravenously into Balb and c mice by tail vein injection .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(34, 0), 'end':(34, 7), 'text':'Ten mice were injected for each construct .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 6), 'text':'Analyses of BaF3 injected mice were performed'}, {'start':(35, 7), 'end':(35, 10), 'text':'as described previously .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(36, 0), 'end':(36, 0), 'text':'Immunoblotting'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(37, 0), 'end':(37, 8), 'text':'HEK293T and BaF3 cells were lysed in a buffer'}, {'start':(37, 9), 'end':(37, 56), 'text':'containing 50 mM sodium phosphate , pH 7.4 , 300 mM NaCl , 1 mM EDTA , 10 mM imidazol , 4 mM sodium vanadate , 2 mM sodium floride , 5 mM benzamidine hydrochloride , 2 mM sodium glycerophosphate and 1 mul ml -1 Triton X-100 ;'}]}, {'start':(37, 57), 'end':(37, 82), 'text':'50 mul ml -1 of glycerol protease inhibitors ( Roche ) and phosphatase inhibitors I and II ( Sigma ) were added immediately before use .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(38, 0), 'end':(38, 5), 'text':'Cells were suspended in lysis buffer'}, {'start':(38, 6), 'end':(38, 13), 'text':'and homogenized by 4-6 bursts of sonication .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(39, 0), 'end':(39, 6), 'text':'Samples were normalized for total protein content'}, {'label':'joint', 'direction':'None', 'children':[{'start':(39, 7), 'end':(39, 34), 'text':'and total cell lysates were clarified by centrifugation for 5 min at 15,000 g. For partial purification , 50 mul of Ni-NTA beads were added to each sample'}, {'start':(39, 35), 'end':(39, 42), 'text':'and incubated 2-4 h at 4 degreesC .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(40, 0), 'end':(40, 9), 'text':'Afterwards , Ni-beads were washed twice with lysis buffer .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(41, 0), 'end':(41, 10), 'text':'Total cell lysates and Ni-bead-purified proteins were suspended in sample buffer'}, {'start':(41, 11), 'end':(41, 16), 'text':'and denatured at 70 degreesC .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(42, 0), 'end':(42, 15), 'text':'For drug treatment , 10 mM stocks of PD166326 and compound 14 in DMSO were used'}, {'start':(42, 16), 'end':(42, 40), 'text':'to supplement the growth media for the desired concentration , 6 x 10 6 cells were treated for each drug concentration for 6 h ,'}]}, {'start':(42, 41), 'end':(42, 47), 'text':'followed by washing with chilled PBS ,'}]}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(42, 48), 'end':(42, 52), 'text':'and crude extracts were prepared'}, {'start':(42, 53), 'end':(42, 56), 'text':'as reported previously .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 0), 'end':(43, 6), 'text':'Proteins were resolved by 7 % SDS-PAGE'}, {'start':(43, 7), 'end':(43, 13), 'text':'( BIORAD ) under denaturing conditions ,'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(43, 14), 'end':(43, 16), 'text':'transferred to nitrocellulose'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(43, 17), 'end':(43, 18), 'text':'and probed'}, {'start':(43, 19), 'end':(43, 21), 'text':'as described .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 0), 'text':'Antibodies'}, {'start':(44, 1), 'end':(44, 5), 'text':'used for immunoblotting were :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 6), 'end':(44, 32), 'text':'anti-EGFR , anti-phospho-EGFR-Y1068 , anti-phospho-EGFR-Y845 , anti-phospho-PDGFRB , anti-phospho-PDGFRA , anti-SRC , anti-phospho-SRC-416 , anti-phospho-SRC-527 , anti-nonphospho-SRC-416 , anti-nonphospho-SRC-527 and anti-phospho-ABL-Y412 , from Cell Signaling Technology ;'}, {'start':(44, 33), 'end':(44, 44), 'text':'anti-phosphotyrosine-PY99 , anti-ABL , anti-PDGFRA and anti-PDGFRB from Santa Cruz Biotechnology .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 5), 'text':'Bands were visualized using ECL reagents'}, {'start':(45, 6), 'end':(45, 8), 'text':'( Pierce )'}]}, {'start':(45, 9), 'end':(45, 15), 'text':'according to the supplier \'s instructions .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 0), 'end':(46, 3), 'text':'Protein preparation and crystallization'}, {'label':'joint', 'direction':'None', 'children':[{'start':(47, 0), 'end':(47, 16), 'text':'Wild-type and T338I mutant chicken c-SRC kinase domains ( residues 251-533 ) were expressed in Escherichia coli'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(47, 17), 'end':(47, 18), 'text':'and purified'}, {'start':(47, 19), 'end':(47, 22), 'text':'as described previously .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 0), 'end':(48, 10), 'text':'Crystals were grown at 25 degreesC by the hanging-drop method ,'}, {'start':(48, 11), 'end':(48, 108), 'text':'mixing 1 mul of protein at a concentration of 10 mg ml -1 ( in 20 mM Tris , pH 8.0 , 100 mM NaCl , 5 % ( v and v ) glycerol , 0.5 mM ( v and v ) Tris - ( 2-carboxyethyl ) phosphine ( TCEP ) , 1 mM ATPgammaS ) with 1 mul well solution ( 10 % ( v and v ) PEG4000 , 50 mM ammonium acetate , 100 mM ( v and v ) Bis-Tris , pH 5.5 , 5 % ( v and v ) glycerol ) .'}]}, {'start':(49, 0), 'end':(49, 15), 'text':'Plate shaped crystals of approximate dimensions 200 mum x 200 mum x 50mum grew overnight .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(50, 0), 'end':(50, 21), 'text':'Crystals were cryoprotected by serial soaks in well solution with increasing glycerol concentration up to 20 % ( v and v )'}, {'label':'joint', 'direction':'None', 'children':[{'start':(50, 22), 'end':(50, 24), 'text':'and snap frozen'}, {'start':(50, 25), 'end':(50, 30), 'text':'and stored in liquid nitrogen .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 0), 'end':(51, 4), 'text':'Data collection and structure determination'}, {'label':'joint', 'direction':'None', 'children':[{'start':(52, 0), 'end':(52, 21), 'text':'Diffraction data were collected at the Advanced Light Source ( ALS ) , Lawrence Berkeley National Laboratory beamlines 8.3.1 and 8.2.1 ,'}, {'start':(52, 22), 'end':(52, 45), 'text':'and processed to a resolution of 2.0 A ( SRC-T338I ) and 2.3 A ( SRC wild type ) with Denzo and Scalepack .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 0), 'end':(53, 46), 'text':'SRC-T338I crystallizes in space group P21 with unit cell dimensions of a = 82.4 A , b = 103.7 A , c = 83.7 A , alpha = gamma = 90degrees , beta = 103.9 degrees and four kinase molecules in the asymmetric unit ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 0), 'end':(54, 47), 'text':'Wild-type SRC crystallizes in space group P21 with unit cell dimensions of a = 42.5 A , b = 119.2 A , c = 63.7 A , alpha = gamma = 90degrees , beta = 90.4 degrees and two kinase molecules in the asymmetric unit ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 0), 'end':(55, 6), 'text':'The structures were solved by molecular replacement'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 7), 'end':(55, 28), 'text':'using the kinase domain of chicken c-SRC residues 250-533 ( PDB 2SRC ) 24 with the C helix and the activation loop'}, {'start':(55, 29), 'end':(55, 38), 'text':'deleted as a search model in the program Phaser .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(56, 0), 'end':(56, 6), 'text':'The models were build in Coot .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(57, 0), 'end':(57, 9), 'text':'SRC-T338I was refined with CNS 1.2 ( ref . )'}, {'start':(58, 0), 'end':(58, 2), 'text':'and Phenix .'}]}]}]}]}, {'start':(59, 0), 'end':(59, 13), 'text':'The R work and R free values are 0.205 and 0.247 , respectively .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 0), 'end':(60, 10), 'text':'Wild-type SRC was refined in REFMAC 5.2 ( ref . )'}, {'start':(61, 0), 'end':(61, 16), 'text':'with TLS refinement with an R work and R free of 19.7 and 0.245 , respectively .'}]}]}]}]}]}
